A reservoir of gold lies hidden in Earth's core. Scientists say it's leaking
Sign up for CNN's Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more.
Gold and other precious metals are leaking from Earth's core into the layers above, eventually making their way up to the surface during the formation of volcanic islands like Hawaii, a new study suggests.
The theory results from a three-year analysis of Hawaii's basaltic rocks, which originally formed from plumes of magma, or molten rock, rising from the ocean floor. Clues in the form of heavy metals found in the volcanic rocks could confirm a suspicion long held by geologists — that Earth's molten core is not isolated but likely bleeds into the rocky mantle, the layer between the planet's thin crust and the core.
'About 40 years ago, people first came up with the theory that maybe the core is losing some material into the mantle, but the signals we got so far were really ambiguous,' said Nils Messling, a geochemist at the University of Göttingen in Germany and lead author of the report, published May 21 in the journal Nature. 'Now, in my opinion, we have the first very strong evidence that some of the core is actually ending up in the mantle.'
Scientists already knew that most of the gold on the planet — more than 99.95%, according to Messling — lies hidden in the molten core, along with other heavy elements such as platinum. As meteorites bombarded one another in Earth's early history, a reservoir of these precious metals developed when the core formed about 4.5 billion years ago.
But this study suggests that at least a tiny amount of that gold has escaped to the surface, raising the fascinating prospect that, if the leaking continues, more and more of this precious metal could travel from the center of Earth to the crust in the future.
'Our findings not only show that the Earth's core is not as isolated as previously assumed. We can now also prove that huge volumes of super-heated mantle material — several hundreds of quadrillion metric tonnes of rock — originate at the core-mantle boundary and rise to the Earth's surface to form ocean islands like Hawaii,' said study coauthor Matthias Willbold, a professor at the University of Göttingen, in a statement.
To find evidence of this core-mantle interaction, Messling and his coauthors obtained some samples of Hawaiian volcanic rocks from the Smithsonian Institution in Washington, DC.
'Some were taken by a submarine, from a deep sea volcano, but (otherwise) it's basically just very ordinary-looking basaltic rock, very unassuming, that you would find anywhere on Hawaii,' he said. 'We started with half a kilogram (1.1 pounds) of rock, we crushed it into a powder, and then we melted it in the oven with some different chemicals, to end up with a sample in liquid form.'
From that sample, the team extracted all the elements in the platinum group, which includes platinum itself as well as the lesser-known rhodium, palladium, iridium, osmium and ruthenium. The scientists then focused on ruthenium, a silver-gray metal about as rare in Earth's crust as gold.
'The mantle has almost no ruthenium in it,' Messling said. 'It's one of the rarest elements on Earth. But Earth is basically made of meteorites that crashed together, and meteorites (contain) ruthenium, which went into the core when the core formed. So the mantle has next to no ruthenium, and the core has all of the ruthenium. The same with gold and platinum.'
Earth's core has two layers. A hot, solid metal sphere of iron and nickel is roughly 70% the size of the moon, with a radius of about 759 miles (1,221 kilometers). A liquid metal outer core is about 1,400 miles (2,253 kilometers) thick and extends to about 1,800 miles (2,897 kilometers) below the surface, or right up to the mantle.
In contrast, the mantle, which lies between the planet's outer crust and the molten core, is 1,800 miles (2,897 kilometers) of mostly solid rock.
To determine whether the extracted ruthenium was originally from the core and not the mantle, the team looked at a specific isotope, or type, of ruthenium that was likely more abundant in Earth's early building materials during the time the core formed billions of years ago.
'The vast majority of gold and other precious metals like platinum were likely delivered by massive meteorite impacts during the final stages of Earth's formation — a process known as late accretion,' said Pedro Waterton, an assistant professor of geochemistry at the University of Copenhagen in Denmark who was not involved in the study.
The presence of the ruthenium isotope in the basalt samples indicates that at least some of the rock was formed from material coming from the molten metallic core.
That's because there is consensus, Messling said, that the material that coalesced during the early stages of Earth's formation does not exist in the meteorite record anymore. He added that the isotope signature in rocks from hotspot volcanoes like the ones in Hawaii is entirely different from any other known rock or meteorite.
In other words, the ruthenium isotope Messling found was locked away in the core billions of years ago, so detecting the isotope in volcanic rocks today suggests it comes from the core.
'It's quite a novel and difficult method,' Messling said. 'We managed to measure ruthenium in rocks that have next to no ruthenium in them. In half a kilo (1.1 pounds) of rock, it was less than milligrams — a needle in a planet-sized haystack! That's quite exciting — for a geochemist, at least. It was a long but very exciting process.'
So what's the connection with gold? It's chemically similar to ruthenium, Messling said, so if the core is leaking ruthenium, it is also leaking gold in similar quantities. This would be a 'minuscule' amount, however. And even if scientists wanted to extract gold directly from the source, the core-mantle boundary, that's much farther down than current technology could drill. In fact, it's about 236 times deeper than the deepest bore ever drilled — the Kola Superdeep Borehole in Russia, which reaches a depth of 7.62 miles (12.3 kilometers).
Proof that the core isn't isolated is particularly thrilling because the core and the mantle shouldn't interact at all, Messling said. 'Their density is too different, like oil and water, so technically they shouldn't mix. And we still don't have a good mechanism to explain why they do. We don't really know much about the core at all,' he said.
The Hawaiian rock samples suggest that the leaking process takes between 500 million and 1 billion years to complete, Messling said.
'It's something that has occurred a while ago, and we suspect that it probably has been going on forever, and it's probably still occurring now,' he explained.
According to Messling, if the leaking of precious metals is an ongoing process, it could be that at least some of the gold humans have mined may have come from the core even if the quantity of core material in a single rock is negligible, and that the world's supply of gold seems to be replenishing.
'It's a very interesting idea that, although this process is tiny and has zero effect if you look at just one island, if you scale it up to 4.5 billion years it could be that it changes the composition of the Earth,' he said.
Researchers who were not involved in the study expressed positive views on the findings.
'We know that the Earth was built from different generations of meteoritic material that were added progressively to the growing planet, and that precious metals from the earliest generations of meteorite material became concentrated into our planet's core while metals from meteorites added in the final stages of the Earth's growth became stranded in our planet's mantle,' said Helen Williams, a professor of geochemistry and planetary science at the University of Cambridge in the United Kingdom.
The study, she added, confirms that the mantle plumes — rising jets of molten rock coming from the core-mantle boundary that create hot spots like Hawaii — do indeed contain material somehow derived from Earth's metallic core, said Williams, adding that the result was 'exciting.'
Jesse Reimink, an associate professor of geosciences at Pennsylvania State University, agrees. 'This is a very old debate, and new data over the past 10 or so years has reinvigorated the possibility that the core was chemically 'leaking' into the mantle over time,' he said. 'This study really does seem to nail the conclusion — the core does contribute some material to the mantle.'
The latest research also strengthens the case made in previous work that some mantle plumes incorporate material from Earth's core, said the University of Copenhagen's Waterton.
Does that also mean some of the gold in Earth's crust is originally from the core? 'Yes, but probably only a very small amount,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – BOSTON, June 20, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. "These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year." "It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events," said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. "As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future." About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About ZimislecelZimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Investor Event and Webcast Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website. View source version on Contacts Vertex Pharmaceuticals IncorporatedInvestors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275
Yahoo
an hour ago
- Yahoo
Lawmakers propose ban on controversial item for sale at many pet stores — here's what you need to know
New York state lawmakers have proposed a new bill to restrict the sale of captive birds throughout the state. According to World Animal News, Assembly Member Linda Rosenthal proposed Assembly Bill A8327, which would ban the sale of birds in pet stores across the state, except for certain domesticated bird species. The new legislation would build on current laws that already restrict the sale of dogs, cats, and rabbits in retail pet shops. While selling animals in a pet shop may not seem like a bad idea, the truth is that the animals are often kept in less-than-ideal conditions and seldom receive adequate veterinary care prior to being sold by the store. On top of that, the sale of birds is complicated by the fact that the vast majority of birds sold in pet shops, like parrots, parakeets, and finches, are not ethically obtained. They are found by wildlife trafficking networks that can occasionally operate in legal gray areas, and with little to no regard for wild bird populations. Removing these birds from their native ecosystems can have a cascading impact on those ecosystems, and can push those birds closer to threatened or endangered levels in the wild. Their transit from their native habitats to the pet stores is seldom done responsibly, and often puts the animals' lives at risk. If that weren't enough, oftentimes birds like parrots struggle in captivity, dealing with immense levels of stress that can cause them to lose feathers and even die. Fortunately, legislation is being discussed to help combat the wildlife trade. On the national level, a bill is under discussion that would help provide resources for trafficked animals to receive the care they need after being seized by the government. New York has also recently passed stricter laws on the trafficking and sale of animals, giving stricter punishments to those found guilty of animal cruelty. Legislation like what's being put forth in New York will help to combat the wildlife trade and keep these birds where they belong, in their native ecosystems. Do you think people should be allowed to keep exotic animals as pets? Yes No It depends on the animal It depends on the person Click your choice to see results and speak your mind. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
an hour ago
- Yahoo
'Teacher,' 'Companion': Grade 1 Winner Forbidden Apple Dies At 30
'Teacher,' 'Companion': Grade 1 Winner Forbidden Apple Dies At 30 originally appeared on Paulick Report. The Thoroughbred Retirement Foundation (TRF) is deeply saddened to share the passing of Forbidden Apple, a cherished 30-year-old member of the TRF herd. Forbidden Apple was humanely euthanized on Monday, June 16, due to the infirmities of old age. Arriving at the TRF's Second Chances Program at Lowell Correctional Facility in Ocala, Florida on Aug. 2, 2013, Forbidden Apple spent the last 12 years of his life teaching, healing, and inspiring the incarcerated women of Lowell, who cared for him daily.A Grade 1 winner with lifetime earnings of $1.6 million, Forbidden Apple made 31 career starts, including three appearances in the prestigious Breeders' Cup Mile. Known for his brilliance on the turf, Forbidden Apple raced with heart and consistency, earning his place among racing's elite. His time after racing was just as important as his time on the track. At Lowell, Forbidden Apple, affectionately known as 'Apple,' quickly became a favorite among Second Chances Program students and staff. His gentle demeanor, playful nature, and deep love for treats and grooming brushes made him both a teacher and a companion to all who knew in all the right ways, Forbidden Apple enjoyed a peaceful retirement, surrounded by people who loved and cared for him every day. Whether trotting across the pasture or gently nosing a brush from a student's pocket, Forbidden Apple found a forever place in the hearts of everyone he Apple lived a long and meaningful life, filled with success, love, and sanctity. The TRF family is especially grateful for the years he spent at Lowell, gently guiding and teaching the women in our Second Chances Program, and being a steady, four-legged friend to all who knew him. To learn more about the TRF Second Chances Program or to support the care of horses like Forbidden Apple, please visit: TRF: Founded in 1983, the Thoroughbred Retirement Foundation is a national organization devoted to dignified lifetime care for retired Thoroughbred racehorses. As the oldest Thoroughbred rescue in the country, the TRF provides sanctuary to retired Thoroughbreds throughout their entire known for its pioneering TRF Second Chances program, the organization provides incarcerated individuals with vocational training through its accredited equine care and stable management program. At seven correctional facilities across the country this program offers second careers to its horses and a second chance at life for inmates upon release from cares for approximately 400 rescued and retired Thoroughbreds at Second Chances prison farms and Sanctuary Farms across the country. The organization is funded entirely by private donations. The TRF is accredited by Thoroughbred Aftercare Alliance and has a Platinum rating with Guide Star. For more information visit: This story was originally reported by Paulick Report on Jun 20, 2025, where it first appeared.
